What is the best treatment for hip fracture prevention in a 78-year-old healthy woman with a lumbar T-score of -2.0 and a right femoral neck T-score of -1.5?

Best Treatment: Oral Alendronate or Subcutaneous Denosumab

For this 78-year-old woman with osteoporosis (lumbar T-score -2.0) and high fracture risk based on age alone, pharmacologic therapy with either oral alendronate or subcutaneous denosumab is strongly recommended to prevent hip fractures, with the choice depending primarily on patient adherence capability and tolerability. 1, 2

Why This Patient Requires Treatment

This patient meets multiple criteria for pharmacologic intervention:

• Age 78 is itself a major risk factor with hazard ratio of 1.35 per 5-year age increase 3
• Lumbar spine T-score of -2.0 meets osteoporosis threshold (T-score ≤ -2.5 OR between -1.0 and -2.5 with elevated FRAX risk) 1, 2
• Femoral neck T-score of -1.5 in a 78-year-old woman likely translates to >3% 10-year hip fracture risk on FRAX calculation, meeting U.S. treatment thresholds 1, 4

First-Line Pharmacologic Options

Oral Alendronate (Preferred if adherent)

• Reduces hip fractures by 50% over 3 years 5
• Demonstrates efficacy for vertebral, non-vertebral, AND hip fractures 6, 1
• Dosing: 70 mg weekly or 10 mg daily 7
• Cost-effective as generic formulation available 6
• Requires strict administration: take on empty stomach, remain upright 30 minutes, adequate hydration 7

Subcutaneous Denosumab (Alternative for adherence concerns)

• 60 mg subcutaneously every 6 months 6, 8
• Reduced fractures by 50% in postmenopausal women independent of baseline BMD 8
• Demonstrates hip, vertebral, and non-vertebral fracture reduction 6, 1
• Superior choice if: oral intolerance, dementia, malabsorption, or adherence concerns 6
• Critical caveat: requires transition to bisphosphonate upon discontinuation to prevent rebound bone loss 6

Why Other Options Are Inappropriate

Repeat Bone Density in 1 Year: INCORRECT

• Patient already meets treatment criteria; delaying therapy increases fracture risk
• At age 78 with osteoporosis, observation is not appropriate 1, 2

Transdermal Climara (Estrogen) and Oral Progesterone: INCORRECT

• Hormone therapy reduces hip fractures in younger postmenopausal women but is limited by cardiovascular and thromboembolic risks 9
• Not recommended as first-line osteoporosis treatment 1
• At age 78 (likely 24+ years post-menopause), risks outweigh skeletal benefits

Oral Calcium and Vitamin D Alone: INCORRECT

• Calcium alone has no demonstrated fracture reduction effect 6, 10
• Vitamin D 800 IU/day with calcium reduces non-vertebral fractures by 15-20% but is insufficient as monotherapy 6
• These are adjunctive measures, not primary treatment 7, 1
• Should be prescribed alongside pharmacologic therapy: 1200 mg calcium daily, 800-1000 IU vitamin D daily 7, 6

Practical Implementation Algorithm

Step 1: Assess adherence capability

• Can patient reliably take weekly oral medication with strict instructions?
  • YES → Start oral alendronate 70 mg weekly
  • NO (cognitive impairment, complex medication regimen, prior non-adherence) → Start denosumab 60 mg SC every 6 months

Step 2: Ensure adequate calcium/vitamin D

• Total calcium intake 1200 mg/day (diet + supplement if needed) 7, 6
• Vitamin D 800-1000 IU daily 7, 6

Step 3: Address non-pharmacologic factors

• Weight-bearing and resistance exercise 1, 2
• Fall prevention assessment (particularly critical at age 78) 1, 2
• Smoking cessation if applicable 1

Step 4: Monitoring

• Repeat DXA in 1-2 years to assess treatment response 2
• Reassess fracture risk at 3-5 years to determine continuation vs. drug holiday (for bisphosphonates only) 4

Critical Pitfalls to Avoid

1. Do not use calcium/vitamin D as sole therapy - this is inadequate for established osteoporosis 6, 10

2. If choosing denosumab, plan transition strategy - abrupt discontinuation causes rapid bone loss and rebound fracture risk; must transition to bisphosphonate 6

3. Ensure dental health before starting - both bisphosphonates and denosumab carry small risk of osteonecrosis of jaw; dental evaluation recommended 8

4. For alendronate, screen for contraindications: esophageal abnormalities, inability to remain upright 30 minutes, hypocalcemia 7

5. Do not delay treatment for "borderline" T-scores - age 78 with T-score -2.0 clearly warrants intervention 1, 2

The evidence strongly supports that bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab are the only agents with proven hip fracture reduction in this population 6, 1, 2. Among oral options, alendronate has the longest track record and lowest cost 6. Denosumab offers convenience and efficacy when oral therapy is not feasible 6, 8.